Prophylactic Human Papillomavirus Vaccination: A Breakthrough in Primary Cervical Cancer Prevention

Obstetrics and Gynecology Clinics of North America

Volumn 34, Issue 4, 2007, Pages 761-781

  Garcia, Francisco A R ^a   Saslow, Debbie ^b  

^a Obstetrics and Gynecology   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

BRONCHOSPASM; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DISEASE TRANSMISSION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; HYPERTENSION; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LARYNX PAPILLOMATOSIS; NAUSEA; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA BLEEDING;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY PREVENTION; SAFETY; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 36549029868     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2007.09.007     Document Type: Review

References (116)

1. Weinstock H., Berman S., and Cates Jr. W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 36 1 (Jan-Feb 2004) 6-10
2. Cates Jr. W. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 26 4 Suppl (Apr 1999) S2-S7
3. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 102 5A (May 5 1997) 3-8
4. Bauer H.M., Ting Y., Greer C.E., et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. Jama 265 4 (Jan 23-30 1991) 472-477
5. Ho G.Y., Bierman R., Beardsley L., Chang C.J., and Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 7 (Feb 12 1998) 423-428
6. Kulasingam S.L., Hughes J.P., Kiviat N.B., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. Jama 288 14 (Oct 9 2002) 1749-1757
7. Richardson H., Kelsall G., Tellier P., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12 6 (Jun 2003) 485-490
8. Myers E.R., McCrory D.C., Nanda K., Bastian L., and Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151 12 (Jun 15 2000) 1158-1171
9. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (Sep 1999) 12-19
10. Bosch F.X., Manos M.M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 11 (Jun 7 1995) 796-802
11. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 6 (Feb 6 2003) 518-527
12. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89 1 (Jul 7 2003) 101-105
13. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (Mar-Apr 2005) 74-108
14. Human Papillomavirus Infection and cervical cancer. World Health Organization. Geneva, Switzerland; 2006.
15. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (Mar-Apr 2006) 106-130
16. Daling J.R., Madeleine M.M., Johnson L.G., et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101 2 (Jul 15 2004) 270-280
17. Schiffman M., and Kjaer S.K. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2 31 (2003) 14-19
18. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24S3 (Aug 21 2006) S1-S10
19. Trimble C.L., Hildesheim A., Brinton L.A., Shah K.V., and Kurman R.J. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol 87 1 (Jan 1996) 59-64
20. Rubin M.A., Kleter B., Zhou M., et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159 4 (Oct 2001) 1211-1218
21. Daling J.R., Madeleine M.M., Schwartz S.M., et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 84 2 (Feb 2002) 263-270
22. Cupp M.R., Malek R.S., Goellner J.R., Espy M.J., and Smith T.F. Detection of human papillomavirus DNA in primary squamous cell carcinoma of the male urethra. Urology 48 4 (Oct 1996) 551-555
23. Forastiere A.A., Ang K., Brizel D., et al. Head and neck cancers. J Natl Compr Canc Netw 3 3 (May 2005) 316-391
24. Herrero R., Castellsague X., Pawlita M., et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95 23 (Dec 3 2003) 1772-1783
25. Kreimer A.R., Clifford G.M., Boyle P., and Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 2 (Feb 2005) 467-475
26. Moscicki A.B. Impact of HPV infection in adolescent populations. J Adolesc Health 37 6 Suppl (Dec 2005) S3-S9
27. Greer C.E., Wheeler C.M., Ladner M.B., et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 33 8 (Aug 1995) 2058-2063
28. Munk C., Svare E.I., Poll P., Bock J.E., and Kjaer S.K. History of genital warts in 10,838 women 20 to 29 years of age from the general population. Risk factors and association with Papanicolaou smear history. Sex Transm Dis 24 10 (Nov 1997) 567-572
29. Workowski K.A., and Berman S.M. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55 RR-11 (Aug 4 2006) 1-94
30. Cubilla A.L., Velazques E.F., Reuter V.E., Oliva E., Mihm Jr. M.C., and Young R.H. Warty (condylomatous) squamous cell carcinoma of the penis: a report of 11 cases and proposed classification of 'verruciform' penile tumors. Am J Surg Pathol 24 4 (Apr 2000) 505-512
31. Reeves W.C., Ruparelia S.S., Swanson K.I., Derkay C.S., Marcus A., and Unger E.R. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 129 9 (Sep 2003) 976-982
32. Go C., Schwartz M.R., and Donovan D.T. Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression. Ann Otol Rhinol Laryngol 112 4 (Apr 2003) 298-302
33. Silver R.D., Rimell F.L., Adams G.L., Derkay C.S., and Hester R. Diagnosis and management of pulmonary metastasis from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 129 6 (Dec 2003) 622-629
34. Lele S.M., Pou A.M., Ventura K., Gatalica Z., and Payne D. Molecular events in the progression of recurrent respiratory papillomatosis to carcinoma. Arch Pathol Lab Med 126 10 (Oct 2002) 1184-1188
35. Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52 6 (Nov-Dec 2002) 342-362
36. Cervix Cancer Screening Vol. 10 (2005), IARC Press, Lyon
37. Devesa S.S. Descriptive epidemiology of cancer of the uterine cervix. Obstet Gynecol 63 5 (May 1984) 605-612
38. Ries L, Harkins D, Krapcho M, A M, Miller B, Feuer E. SEER Cancer Statistics Review, 1975-2003. National Cancer Institute Bethesda, MD; 2006.
39. Nanda K., McCrory D.C., Myers E.R., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 132 10 (May 16 2000) 810-819
40. Stoler M.H., and Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. Jama 285 11 (Mar 21 2001) 1500-1505
41. Sawaya G.F., and Washington A.E. Cervical cancer screening: which techniques should be used and why?. Clin Obstet Gynecol 42 4 (Dec 1999) 922-938
42. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 105 4 (Apr 2005) 905-918
43. Leyden W.A., Manos M.M., Geiger A.M., et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 97 9 (May 4 2005) 675-683
44. Schwartz P.E., Hadjimichael O., Lowell D.M., Merino M.J., and Janerich D. Rapidly progressive cervical cancer: the Connecticut experience. Am J Obstet Gynecol 175 4 Pt 2 (Oct 1996) 1105-1109
45. Parham G.P., and Hicks M.L. Racial disparities affecting the reproductive health of African-American women. Med Clin North Am 89 5 (Sep 2005) 935-943 941
46. Patel D.A., Barnholtz-Sloan J.S., Patel M.K., Malone Jr. J.M., Chuba P.J., and Schwartz K. A population-based study of racial and ethnic differences in survival among women with invasive cervical cancer: analysis of Surveillance, Epidemiology, and End Results data. Gynecol Oncol 97 2 (May 2005) 550-558
47. Singh G.K., Miller B.A., Hankey B.F., and Edwards B.K. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer 101 5 (Sep 1 2004) 1051-1057
48. Hall H.I., Jamison P.M., and Coughlin S.S. Breast and cervical cancer mortality in the Mississippi Delta, 1979-1998. South Med J 97 3 (Mar 2004) 264-272
49. Coronado G.D., Thompson B., Koepsell T.D., Schwartz S.M., and McLerran D. Use of Pap test among Hispanics and non-Hispanic whites in a rural setting. Prev Med 38 6 (Jun 2004) 713-722
50. Yabroff K.R., Lawrence W.F., King J.C., et al. Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment?. J Rural Health 21 2 (Spring 2005) 149-157
51. Freeman H.P., and Chu K.C. Determinants of cancer disparities: barriers to cancer screening, diagnosis, and treatment. Surg Oncol Clin N Am 14 4 (Oct 2005) 655-669 v
52. Freeman H, Wingrove B. Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities: National Institutes of Health; 2005.
53. Seeff L.C., and McKenna M.T. Cervical cancer mortality among foreign-born women living in the United States, 1985 to 1996. Cancer Detect Prev 27 3 (2003) 203-208
54. Kitchener H.C., Castle P.E., and Cox J.T. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 24 Suppl. 3 (Aug 21 2006) S63-S70
55. Clark L.R., Jackson M., and Allen-Taylor L. Adolescent knowledge about sexually transmitted diseases. Sex Transm Dis 29 8 (Aug 2002) 436-443
56. Dell D.L., Chen H., Ahmad F., and Stewart D.E. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 96 5 Pt 1 (Nov 2000) 653-656
57. Mays R.M., Zimet G.D., Winston Y., Kee R., Dickes J., and Su L. Human papillomavirus, genital warts, Pap smears, and cervical cancer: knowledge and beliefs of adolescent and adult women. Health Care Women Int 21 5 (Jul-Aug 2000) 361-374
58. Baer H., Allen S., and Braun L. Knowledge of human papillomavirus infection among young adult men and women: implications for health education and research. J Community Health 25 1 (Feb 2000) 67-78
59. Denny-Smith T., Bairan A., and Page M.C. A survey of female nursing students' knowledge, health beliefs, perceptions of risk, and risk behaviors regarding human papillomavirus and cervical cancer. J Am Acad Nurse Pract 18 2 (Feb 2006) 62-69
60. Lambert E.C. College students' knowledge of human papillomavirus and effectiveness of a brief educational intervention. J Am Board Fam Pract 14 3 (May-Jun 2001) 178-183
61. Ramirez J.E., Ramos D.M., Clayton L., Kanowitz S., and Moscicki A.B. Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a nonclinic population of young women. J Womens Health 6 1 (Feb 1997) 113-121
62. Yacobi E., Tennant C., Ferrante J., Pal N., and Roetzheim R. University students' knowledge and awareness of HPV. Prev Med 28 6 (Jun 1999) 535-541
63. Waller J., McCaffery K., Forrest S., Szarewski A., Cadman L., and Wardle J. Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect 79 4 (Aug 2003) 320-322
64. Gerhardt C.A., Pong K., Kollar L.M., Hillard P.J., and Rosenthal S.L. Adolescents' knowledge of human papillomavirus and cervical dysplasia. J Pediatr Adolesc Gynecol 13 1 (Feb 2000) 15-20
65. Le T., Hicks W., Menard C., et al. Human papilloma virus testing knowledge and attitudes among women attending colposcopy clinic with ASCUS/LGSIL pap smears. J Obstet Gynaecol Can 26 9 (Sep 2004) 788-792
66. Pitts M., and Clarke T. Human papillomavirus infections and risks of cervical cancer: what do women know?. Health Educ Res 17 6 (Dec 2002) 706-714
67. Waller J., McCaffery K., Nazroo J., and Wardle J. Making sense of information about HPV in cervical screening: a qualitative study. Br J Cancer 92 2 (Jan 31 2005) 265-270
68. Gilbert L.K., Alexander L., Grosshans J.F., and Jolley L. Answering frequently asked questions about HPV. Sex Transm Dis 30 3 (Mar 2003) 193-194
69. Anhang R., Goodman A., and Goldie S.J. HPV communication: review of existing research and recommendations for patient education. CA Cancer J Clin 54 5 (Sep-Oct 2004) 248-259
70. Hoover D.R., Carfioli B., and Moench E.A. Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int 21 5 (Jul-Aug 2000) 375-391
71. Kahn J.A., Rosenthal S.L., Hamann T., and Bernstein D.I. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 14 5 (May 2003) 300-306
72. Zimet G.D., Mays R.M., Winston Y., Kee R., Dickes J., and Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 9 1 (Jan-Feb 2000) 47-50
73. Davis K., Dickman E.D., Ferris D., and Dias J.K. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 8 3 (Jul 2004) 188-194
74. Mays R.M., Sturm L.A., and Zimet G.D. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med 58 7 (Apr 2004) 1405-1413
75. Olshen E., Woods E.R., Austin S.B., Luskin M., and Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health 37 3 (Sep 2005) 248-251
76. Zimet G.D., Mays R.M., Sturm L.A., Ravert A.A., Perkins S.M., and Juliar B.E. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. Arch Pediatr Adolesc Med 159 2 (Feb 2005) 132-137
77. Mays R.M., and Zimet G.D. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm Dis 31 7 (Jul 2004) 428-432
78. Raley J.C., Followwill K.A., Zimet G.D., and Ault K.A. Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists. Infect Dis Obstet Gynecol 12 3-4 (Sep-Dec 2004) 127-133
79. Gust D.A., Campbell S., Kennedy A., Shui I., Barker L., and Schwartz B. Parental concerns and medical-seeking behavior after immunization. Am J Prev Med 31 1 (Jul 2006) 32-35
80. Kennedy A.M., Brown C.J., and Gust D.A. Vaccine beliefs of parents who oppose compulsory vaccination. Public Health Rep 120 3 (May-Jun 2005) 252-258
81. Dempsey A.F., Zimet G.D., Davis R.L., and Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 117 5 (May 2006) 1486-1493
82. Emeny R.T., Wheeler C.M., Jansen K.U., et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 76 15 (Aug 2002) 7832-7842
83. Pinto L.A., Edwards J., Castle P.E., et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 188 2 (Jul 15 2003) 327-338
84. Kadish A.S., and Einstein M.H. Vaccine strategies for human papillomavirus-associated cancers. Curr Opin Oncol 17 5 (Sep 2005) 456-461
85. Koutsky L.A., Ault K.A., Wheeler C.M., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (Nov 21 2002) 1645-1651
86. Mao C., Koutsky L.A., Ault K.A., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 1 (Jan 2006) 18-27
87. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (Nov 13-19 2004) 1757-1765
88. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (Apr 15 2006) 1247-1255
89. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (May 2005) 271-278
90. Future-II-Study-Group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. NEJM (May 10, 2007) 2007;356(19):1915-27
91. Future-I-Investigators. Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. NEJM (May 10, 2007) 2007;356(19):1928-43
92. FDA. Product Approval Information - Licensing Action (Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine). Rockville, MD; 2007.
93. Carter J.J., Koutsky L.A., Wipf G.C., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174 5 (Nov 1996) 927-936
94. Ho G.Y., Studentsov Y.Y., Bierman R., and Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13 1 (Jan 2004) 110-116
95. Kirnbauer R., Hubbert N.L., Wheeler C.M., Becker T.M., Lowy D.R., and Schiller J.T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86 7 (Apr 6 1994) 494-499
96. FDA. Safety and efficacy of GARDASIL® (Human Papillomavirus [Types 6,11,16,18] Recombinant Vaccine) manufactured by Merck. Vaccines and Related Biological Products Advisory Committee, May 18, 2006. Rockville, MD; 2006.
97. Abma JC, Martinez GM, Mosher WD, Dawson BS. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002. Vital Health Stat 23. Dec 2004(24):1-48.
98. Moscicki A.B., Hills N., Shiboski S., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. Jama 285 23 (Jun 20 2001) 2995-3002
99. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 3 (Feb 1 2003) 218-226
100. Wheeler C.M., Greer C.E., Becker T.M., Hunt W.C., Anderson S.M., and Manos M.M. Short-term fluctuations in the detection of cervical human papillomavirus DNA. Obstet Gynecol 88 2 (Aug 1996) 261-268
101. Brown D.R., Shew M.L., Qadadri B., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191 2 (Jan 15 2005) 182-192
102. Peyton C.L., Gravitt P.E., Hunt W.C., et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 183 11 (Jun 1 2001) 1554-1564
103. Santelli J.S., Brener N.D., Lowry R., Bhatt A., and Zabin L.S. Multiple sexual partners among U.S. adolescents and young adults. Fam Plann Perspect 30 6 (Nov-Dec 1998) 271-275
104. Mosher W.D., Chandra A., and Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data 2005 362 (Sep 15, 2005) 1-55
105. Khan M.J., Castle P.E., Lorincz A.T., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 14 (Jul 20 2005) 1072-1079
106. Castle P.E., Solomon D., Schiffman M., and Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97 14 (Jul 20 2005) 1066-1071
107. Saslow D., Castle P.E., Cox J.T., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57 1 (Jan-Feb 2007) 7-28
108. Goldie S.J., Kohli M., Grima D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 8 (Apr 21 2004) 604-615
109. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. Jama 290 6 (Aug 13 2003) 781-789
110. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 1 (Jan 2003) 37-48
111. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 5 (May 2006) e138
112. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191 Suppl. 1 (Feb 1 2005) S97-S106
113. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., and Unger E.R. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 RR-2 (Mar 23 2007) 1-24
114. Davis M.M., Zimmerman J.L., Wheeler J.R., and Freed G.L. Childhood vaccine purchase costs in the public sector: past trends, future expectations. Am J Public Health 92 12 (2002) 1982-1987
115. Mast E.E., Mahoney F.J., Alter M.J., and Margolis H.S. Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine, elimination of hepatitis B virus transmission in the United States. Vaccine 16 Suppl (1998) S48-S51
116. Franco E.L., and Harper D.M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23 17-18 (Mar 18 2005) 2388-2394